ProCE Banner Activity

AURA-3: CNS Response to Osimertinib in EGFR T790M+ Advanced NSCLC

Slideset Download
Conference Coverage
Osimertinib associated with significantly improved CNS disease control vs platinum/pemetrexed in patients with CNS metastases from advanced NSCLC.

Released: June 09, 2017

Expiration: June 08, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology